MADRID, Spain — New data from three trials evaluating the bispecific antibody amivantamab (Rybrevant) in EGFR-mutated advanced non–small cell lung cancer (NSCLC) have revealed a clear benefit, experts ...

Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials ...

The phase 3 MARIPOSA- 2 study shows significant improvement within progression free survival after implementing Rybrevant into treatment for patients with non-small cell lung cancer. Rybrevant ...

“The positive overall survival trend seen in MARIPOSA-2 suggests that amivantamab combined with chemotherapy could potentially change the treatment landscape for a population that has historically ...

MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and ...

MARIPOSA COUNTY, Calif. (KSEE/KGPE) – Two people were arrested after over 3,000 illegal marijuana plants were found on two illegal cultivation sites in Mariposa County. The Mariposa County Sheriff’s ...

Rybrevant plus chemotherapy improved overall survival versus chemo alone in EGFR-mutant advanced non-small cell lung cancer after disease progression. Promising overall survival (OS) trends continued ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, ...

Johnson & Johnson (J&J) announced that new data from its industry-leading oncology pipeline will be presented at the 2025 European Lung Cancer Congress (ELCC), including overall survival (OS) results ...

High Wycombe, UK (14 September 2024) – Johnson & Johnson today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT ® (amivantamab) combined with chemotherapy led to a ...